Join us as we look back on a decade of ERS Genomics, CRISPR and the IP that made it possible. Over the past 10 years, CRISPR/Cas9 has moved from breakthrough discovery to a foundational platform for modern biology. In parallel, ERS Genomics has grown into the global leader in CRISPR/Cas9.

License enables Dyadic Applied BioSolutions to expand genetic engineering capabilities Dublin, Ireland, and Jupiter FL, USA, 10 November 2025: ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions (‘Dyadic’), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today announced they have.

Merging CRISPR Gene Editing with Agentic AI   A new AI co-pilot automates genome engineering, accelerating discovery and democratizing CRISPR expertise.    Introduction: The Convergence of Two Powerful Technologies  Two of the most transformative technologies of our era, CRISPR/Cas9 gene editing and large language models (LLMs), are converging to reshape.